IMDXMEDIUM SIGNALFINANCIAL10-K

IMDX completed a corporate rebranding from Oncocyte Corporation while showing improved losses but concerning balance sheet deterioration and substantially higher R&D spending.

The company has finalized its product rebranding strategy, moving from in-process changes to completed rebrand implementation, which suggests greater commercial focus and market positioning clarity. However, the combination of meaningfully higher R&D expenses alongside declining total assets and rising current liabilities indicates potential cash flow pressures that warrant monitoring, despite the improved net loss position.

Comparing 2026-03-26 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

IMDX showed mixed financial performance with net losses improving modestly from -$60.7M to -$50.2M, though this was offset by substantially higher R&D expenses. The balance sheet presents concerning trends with current liabilities increasing significantly to $12.1M while total assets declined to $25.8M, creating a tighter liquidity position despite higher cash balances. The substantial increase in R&D spending signals continued investment in product development, but the overall financial picture suggests mounting operational pressures requiring careful cash management.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+66%
$7.3M→$12.1M

Current liabilities surged 66% — significant near-term obligations; verify ability to meet short-term debt.

R&D Expense
P&L
+61.6%
$9.8M→$15.9M

R&D investment increased 61.6% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
+34.1%
$8.6M→$11.6M

Cash position surged 34.1% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+30.2%
$11.8M→$15.3M

Current assets grew 30.2% — improving short-term liquidity or inventory/receivables build.

Accounts Receivable
Balance Sheet
-30.1%
$1.6M→$1.1M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Assets
Balance Sheet
-26.6%
$35.1M→$25.8M

Total assets contracted 26.6% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
+20.8%
$47.4M→$57.2M

Liabilities increased 20.8% — monitor debt-to-equity ratio and interest coverage.

Net Income
P&L
+17.2%
-$60.7M→-$50.2M

Net income grew 17.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+16.2%
-$61.0M→-$51.1M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-24
ADDED
(Exact name of registrant as specified in its charter) California 27-1041563 (State or other jurisdiction of incorporation or organization) (I.R.S.
The forward-looking statements include, among other things, statements about: the timing and potential achievement of future milestones; the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers, including within the U.S.
for the development and commercialization of products; the impact of government laws and regulations, including the impact of a prolonged government shutdown; and our competitive position.
Unless the context otherwise requires, all references to iMDx, we, us, our, the Company or similar words refer to Insight Molecular Diagnostics Inc., together with our consolidated subsidiaries.
We have rebranded our VitaGraft assay (VitaGraft Kidney and VitaGraft Liver), which is our lab developed test, under the name GraftAssureCore.
We also rebranded our kitted research use only assay, GraftAssure, as GraftAssureIQ, and our future kitted clinical assay as GraftAssureDx.
Increased competition from, and technological advances by, our competitors could negatively affect our operating results.
Defects, failures or quality issues associated with our products could lead to product recalls or safety alerts, adverse regulatory actions, product liability lawsuits and other litigation and negative publicity.
We are, and may become, dependent on collaborations to develop and commercialize our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business .
Our business could be adversely affected if we lose the services of the key personnel upon whom we depend.
REMOVED
As of March 17, 2025, there were outstanding 28,599,285 shares of common stock, no par value.
Unless the context otherwise requires, all references to Oncocyte, we, us, our, the Company or similar words refer to Oncocyte Corporation, together with our consolidated subsidiaries.
We are in the process of rebranding our VitaGraft assay (VitaGraft Kidney and VitaGraft Liver), which is our lab developed test, under the name GraftAssureCore.
For purposes of this filing, references to GraftAssureCore shall be deemed to include the test previously marketed as VitaGraft.
We are also in the process of rebranding our research use only assay, GraftAssure, as GraftAssureIQ, and rebranding our future kitted clinical assay as GraftAssureDx.
2 INDUSTRY AND MARKET DATA This Report contains market data and industry forecasts that were obtained from industry publications, third party market research and publicly available information.
3 PART I Summary of Risk Factors We face many risks and uncertainties, as more fully described in this section under the heading Risk Factors.
We may become dependent on possible future collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.
We are subject to state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California.
Our products are subject to the FDA s final rule ending enforcement discretion for LDTs and regulating such tests as medical devices.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →